国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

  .contact us |.about us
News > Lifestyle News ...
Search:
    Advertisement
Cancer vaccine may extend survival
( 2003-08-21 08:51) (China Daily)

The biotechnology company Antigenics Inc said on Monday its experimental cancer vaccine improved survival time in 52 per cent of advanced colon cancer patients who responded to the drug in a small mid-stage clinical trial.

Antigenics, based in New York, said all of the 15 patients who responded immunologically to the vaccine, called Oncophage, were alive two years after treatment, compared with 50 per cent of the 14 patients who did not respond. The disease-free survival rate was 51 per cent for responders and 8 per cent for non-responders.

Typically, patients with advanced colon cancer can expect to live for up to a year, said Garo Armen, chief executive of Antigenics.

"These results are not randomized, but in all the patients who showed an immune response, there has been a trend toward benefit in our clinical trials," he said.

Oncophage is a personalized vaccine derived from an individual patient's tumour. Because the injected drug contains the patient's own genetic codes, it is believed to be more effective in reprogramming the immune system to attack the cancer without side effects.

The vaccine is being studied in a range of cancers, including kidney, pancreatic, skin and gastric cancers.

The first pivotal-stage data on Oncophage is expected later this year, with preliminary results from a Phase 3 kidney cancer trial, Armen said. In that study, patients who have had their cancer surgically removed are either being treated with the vaccine or simply observed, which is the standard of care for patients with that stage of kidney cancer, the CEO explained.

Initial results will be compiled when 80 to 100 of the 600 or so participants have had their cancer return, Armen said. Patients who do relapse are then offered chemotherapy drugs or other toxic therapies.

If the results are promising, Antigenics expects to file for US Food and Drug Administration approval of the vaccine in 2004, he added.

 
Close  
   
  Today's Top News   Top Lifestyle News
   
+Passport application simplified in Beijing
( 2003-08-21)
+Yellow River turns black in first half
( 2003-08-21)
+Land bid plan announced in Shanghai
( 2003-08-21)
+'DIY tourists' swarm to HK, Macao
( 2003-08-21)
+China, WHO join hands in fight against SARS virus
( 2003-08-21)
+Cancer vaccine may extend survival
( 2003-08-21)
+Hope for cancer victims
( 2003-08-21)
+Old band to rock city with new power
( 2003-08-21)
+Tropical storm Vamco reaches east China's Zhejiang Province
( 2003-08-20)
+China's second longest river severely polluted: SEPA
( 2003-08-20)
   
  Go to Another Section  
     
 
 
     
  Article Tools  
     
   
     
   
        .contact us |.about us
  Copyright By chinadaily.com.cn. All rights reserved  

<small id="dzhq3"></small>

    沅江市| 喀什市| 柳州市| 正阳县| 广德县| 运城市| 德江县| 乐平市| 饶阳县| 思南县| 四平市| 丹寨县| 清流县| 兴海县| 竹山县| 新源县| 威海市| 甘德县| 高邮市| 云南省| 临安市| 石阡县| 教育| 封开县| 山东| 来安县| 田东县| 深泽县| 高安市| 苍溪县| 军事| 金山区| 德州市| 腾冲县| 太谷县| 南阳市| 江油市| 策勒县| 鲜城| 海阳市| 惠来县|